Cri­net­ics spins out ra­dio­phar­ma ef­forts in­to a new com­pa­ny, high­light­ing the grow­ing field­'s al­lure

Large­ly known for its non­pep­tide small mol­e­cule re­search, Cri­net­ics has been keep­ing its ra­dio­phar­ma work com­par­a­tive­ly un­der wraps. But that changed Mon­day af­ter­noon as the Cal­i­for­nia biotech spun out a new com­pa­ny fo­cused sole­ly on the bur­geon­ing field.

Cri­net­ics launched Ra­dio­net­ics af­ter the clos­ing bell Mon­day, the com­pa­ny an­nounced, seed­ing the new en­ti­ty with $30 mil­lion raised from 5AM Ven­tures and Fra­zier Health­care Part­ners. Ra­dio­net­ics will start with its own ra­dio­phar­ma-cen­tric plat­form and a pipeline of 10 pro­grams aimed at sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER